Business Description
Tci Gene Inc
ISIN : TW0006879000
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 217.23 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | 0.09 | |||||
Interest Coverage | 14.61 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 7.07 | |||||
Beneish M-Score | -1.96 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.9 | |||||
3-Year EBITDA Growth Rate | -30.9 | |||||
3-Year EPS without NRI Growth Rate | -38.6 | |||||
3-Year FCF Growth Rate | -31.1 | |||||
3-Year Book Growth Rate | 49.7 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.73 | |||||
9-Day RSI | 31.26 | |||||
14-Day RSI | 33.9 | |||||
6-1 Month Momentum % | -25.25 | |||||
12-1 Month Momentum % | -30.38 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.14 | |||||
Quick Ratio | 6.78 | |||||
Cash Ratio | 6.29 | |||||
Days Inventory | 128.16 | |||||
Days Sales Outstanding | 83.1 | |||||
Days Payable | 169.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.78 | |||||
Dividend Payout Ratio | 1.76 | |||||
Forward Dividend Yield % | 1.78 | |||||
5-Year Yield-on-Cost % | 1.78 | |||||
3-Year Average Share Buyback Ratio | -12.2 | |||||
Shareholder Yield % | 1.8 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 54.41 | |||||
Operating Margin % | 3.87 | |||||
Net Margin % | 7.86 | |||||
FCF Margin % | -1.33 | |||||
ROE % | 2.75 | |||||
ROA % | 2.29 | |||||
ROIC % | 9.15 | |||||
3-Year ROIIC % | -40.02 | |||||
ROC (Joel Greenblatt) % | 127.46 | |||||
ROCE % | 3.59 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 54.37 | |||||
PE Ratio without NRI | 49.34 | |||||
Price-to-Owner-Earnings | 212.45 | |||||
PS Ratio | 4.26 | |||||
PB Ratio | 1.42 | |||||
Price-to-Tangible-Book | 1.43 | |||||
EV-to-EBIT | 13.5 | |||||
EV-to-EBITDA | 9.62 | |||||
EV-to-Revenue | 1.42 | |||||
EV-to-FCF | -108.72 | |||||
Price-to-Graham-Number | 1.77 | |||||
Price-to-Net-Current-Asset-Value | 1.57 | |||||
Price-to-Net-Cash | 1.83 | |||||
Earnings Yield (Greenblatt) % | 7.41 | |||||
FCF Yield % | -0.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Tci Gene Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil NT$) | 348.504 | ||
EPS (TTM) (NT$) | 1.03 | ||
Beta | 0 | ||
Volatility % | 15.86 | ||
14-Day RSI | 33.9 | ||
14-Day ATR (NT$) | 1.142524 | ||
20-Day SMA (NT$) | 59.38 | ||
12-1 Month Momentum % | -30.38 | ||
52-Week Range (NT$) | 56 - 93.9 | ||
Shares Outstanding (Mil) | 26.46 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Tci Gene Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Tci Gene Inc Stock Events
Event | Date | Price(NT$) | ||
---|---|---|---|---|
No Event Data |
Tci Gene Inc Frequently Asked Questions
What is Tci Gene Inc(ROCO:6879)'s stock price today?
When is next earnings date of Tci Gene Inc(ROCO:6879)?
Does Tci Gene Inc(ROCO:6879) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |